| Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. | |
| | |
MedLine Citation:
|
PMID: 20237510 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To test whether fast-acting, self-complimentary (sc), adeno-associated virus-mediated RPE65 expression prevents cone degeneration and/or restores cone function, we studied two mouse lines: the Rpe65-deficient rd12 mouse and the Rpe65-deficient, rhodopsin null ('that is, cone function-only') Rpe65(-/-)::Rho(-/-) mouse. scAAV5 expressing RPE65 was injected subretinally into one eye of rd12 and Rpe65(-/-)::Rho(-/-) mice at postnatal day 14 (P14). Contralateral rd12 eyes were injected later, at P35. Rd12 behavioral testing revealed that rod vision loss was prevented with either P14 or P35 treatment, whereas cone vision was only detected after P14 treatment. Consistent with this observation, P35 treatment only restored rod electroretinogram (ERG) signals, a result likely due to reduced cone densities at this time point. For Rpe65(-/-)::Rho(-/-) mice in which there is no confounding rod contribution to the ERG signal, cone cells and cone-mediated ERGs were also maintained with treatment at P14. This work establishes that a self-complimentary AAV5 vector can restore substantial visual function in two genetically distinct models of Rpe65 deficiency within 4 days of treatment. In addition, this therapy prevents cone degeneration but only if administered before extensive cone degeneration, thus supporting continuation of current Leber's congenital amaurosis-2 clinical trials with an added emphasis on cone subtype analysis and early intervention. |
| | |
Authors:
|
J Pang; S E Boye; B Lei; S L Boye; D Everhart; R Ryals; Y Umino; B Rohrer; J Alexander; J Li; X Dai; Q Li; B Chang; R Barlow; W W Hauswirth |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. Date: 2010-03-18 |
Journal Detail:
|
Title: Gene therapy Volume: 17 ISSN: 1476-5462 ISO Abbreviation: Gene Ther. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-09-27 Revised Date: 2012-05-28 |
Medline Journal Info:
|
Nlm Unique ID: 9421525 Medline TA: Gene Ther Country: England |
Other Details:
|
Languages: eng Pagination: 815-26 Citation Subset: IM |
Affiliation:
|
Department of Ophthalmology and Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA. jpang@ufl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Carrier Proteins / physiology* Dependovirus / genetics* Disease Models, Animal Eye Proteins / physiology* Gene Therapy* Genetic Vectors Mice Optic Atrophy, Hereditary, Leber / therapy* Retinal Cone Photoreceptor Cells / physiology* Retinal Degeneration / genetics*, prevention & control* |
| Grant Support | |
ID/Acronym/Agency:
|
EY00067/EY/NEI NIH HHS; EY014046/EY/NEI NIH HHS; EY017246/EY/NEI NIH HHS; EY018331/EY/NEI NIH HHS; EY06360/EY/NEI NIH HHS; EY07758/EY/NEI NIH HHS; EY08571/EY/NEI NIH HHS; EY11123/EY/NEI NIH HHS; EY13729/EY/NEI NIH HHS; F32 EY017246-03/EY/NEI NIH HHS; NS36302/NS/NINDS NIH HHS; P30 EY008571-20S1/EY/NEI NIH HHS; R01 EY007758-20/EY/NEI NIH HHS; R01 EY011123-15/EY/NEI NIH HHS; R01 EY019943-02/EY/NEI NIH HHS; R21 EY018331-02/EY/NEI NIH HHS; U10 EY013729-05/EY/NEI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Carrier Proteins; 0/Eye Proteins; EC 3.1.1.64/retinoid isomerohydrolase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with met...
Next Document: Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcripti...